![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
J. Lalezari1, L. Holland1, E. Glutzer1, P. Vig2, M. Elgadi3, J.O. Stern3, R. Colonno2, S. Halfon2, E. Ruby2, N. Huang2, E. Nash2, and N. Brown2
1Quest Clinical Research (San Francisco, CA, U.S.A.); 2Presidio Pharmaceuticals (San Francisco, CA, U.S.A.); 3Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT, U.S.A.)
![EASL1.gif](../images/041414/041414-11/EASL1.gif)
![EASL2.gif](../images/041414/041414-11/EASL2.gif)
![EASL3.gif](../images/041414/041414-11/EASL3.gif)
![EASL4.gif](../images/041414/041414-11/EASL4.gif)
![EASL5.gif](../images/041414/041414-11/EASL5.gif)
![EASL6.gif](../images/041414/041414-11/EASL6.gif)
![EASL7.gif](../images/041414/041414-11/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|